Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of share price manipulation of Biovail, a Canadian pharmaceutical company. Gradient and BofA is negative earnings reports Biovail's quality. At the same time, SAC built a large short position in the stock. Defendants must consider the outcomes and policy responses to these charges. "Hide
by Malcolm P. Baker, Christopher J. Lombardi, Aldo Sesia Source: Harvard Business School 14 pages. Publication Date: November 7, 2006. Prod. #: 207071-PDF-ENG
Related Case Solutions & Analyses:
The Launch of Bacardi Silver
Simons Hostile Tender for Taubman (B)
Apple Computer 2005
Game Theory and Business Strategy
Newsprint Industry
Venture Capital and Private Equity Course Overview
Dividend Policy At Linear Technology
Wausau Equipment Company: A Lean Journey (C)
Essay
Ford Motor Company: Accounting for Deferred Taxes
